About Us

Mission & Vision

Empowering diagnostic innovation through end-to-end CDMO expertise, from scientific vision to market reality.

Mission

At Helio Diagnostics, our mission is to empower diagnostic solutions providers by delivering end-to-end CDMO solutions: from early feasibility and assay development to industrialization, manufacturing, regulatory support, and lifecycle management.

We exist to help great diagnostic ideas reach the patients who need them.

Vision

Our vision is to become the leading European CDMO for In Vitro Diagnostics (IVDs): setting new standards of quality, trust, and partnership across the full IVD value chain.

We aim to deliver end-to-end excellence, recognized for our scientific expertise, operational reliability, and customer-centric approach.

Helio Diagnostics strives to be the partner of choice for diagnostic innovators worldwide, helping them bring cutting-edge solutions to market quickly, efficiently, and with the highest quality standards.

Leadership Team

25+ years of IVD experience. A seasoned team making innovation operational.

Stéphane Debono

President & CEO

Entrepreneur and life sciences leader with a proven track record of building diagnostic companies in Europe. Stéphane is an accomplished leader in the diagnostics industry with 25+ years of experience spanning operations, product development, and executive management. He began his career in molecular diagnostics and played a key role in the growth of HalioDx, where he served as Deputy CEO and later as General Manager within Veracyte following its acquisition. Recognized for his ability to bridge scientific innovation and industrial execution, Stéphane has successfully led teams through international integrations and large-scale operational transitions. As CEO of Helio Diagnostics, he is driving the company’s transformation into Europe’s leading CDMO for in vitro diagnostics, combining technical excellence, customer focus, and a vision of trusted long-term partnership.

Dejan Drljaca

Chief Business Officer

With 20+ years of leadership in commercial and marketing roles, Dejan has built a strong international track record across diagnostics companies in Europe and the Americas. His career includes senior positions at QIAGEN, Hologic, HalioDx, Veracyte, and Eurobio Scientific, where he most recently served as Chief Commercial Officer. He has successfully built and led international sales and marketing organizations, developed strategic partnerships, and driven business growth across Europe, North America, and Latin America. With a long-standing connection to Marseille dating back to his early career at Ipsogen, Dejan brings both global perspective and local roots. At Helio Diagnostics, he leads business development and partnership efforts, supporting the company’s ambition to become a leading European CDMO for in vitro diagnostics.

Fabienne Hermitte

CSO - Head of Quality & Regulatory Affairs

Specialist in Clinical, Medical & Regulatory Affairs with 25+ years of expertise in bringing IVD products to market. Fabienne has an extensive background in regulatory affairs and clinical development for diagnostics. At HalioDx, she led medical, clinical and regulatory initiatives that enabled the development, validation, and global deployment of innovative immuno-oncology diagnostic solutions. She masters quality systems regulations (ISO13485, IVDR, FDA, MDSAP). With a track record in oncology, immunology, infectious diseases and neurology, from biomarker development to international submissions, she is a recognized specialist in bringing IVD products to market under rigorous standards. At Helio Diagnostics, Fabienne provides strategic guidance on regulatory and quality excellence, supporting the company’s mission to deliver reliable, compliant, and innovative CDMO services.

Leila Boujadaine

Chief Financial Officer

With 20+ years of experience in the life sciences and diagnostics industry, Leila has developed strong expertise in finance, operations, and strategic management. She began her career at Ipsogen and later QIAGEN Marseille, where she built strong expertise in financial management and corporate operations. At HalioDx, she played a key role as Finance & HR Director, supporting the company’s growth and international integration until its acquisition by Veracyte. Most recently, she served as Finance Director Europe at Albhades, a pharmaceutical and life sciences services group. At Helio Diagnostics, Leïla will assume the role of Chief Financial Officer, bringing her deep financial expertise and governance experience to support the company’s expansion as a leading European CDMO for in vitro diagnostics.

Board of Directors

Guided by a board of veteran experts with deep industry knowledge.

Stéphane Debono

Entrepreneur and life sciences leader, proven track record of building diagnostic companies in Europe (Ipsogen, Qiagen, HalioDx, Veracyte)

Stéphane is an accomplished leader in the diagnostics industry with 25+ years of experience spanning operations, product development, and executive management. He began his career in molecular diagnostics and played a key role in the growth of HalioDx, where he served as Deputy CEO and later as General Manager within Veracyte following its acquisition. Recognized for his ability to bridge scientific innovation and industrial execution, Stéphane has successfully led teams through international integrations and large-scale operational transitions. As CEO of Helio Diagnostics, he is driving the company’s transformation into Europe’s leading CDMO for in vitro diagnostics, combining technical excellence, customer focus, and a vision of trusted long-term partnership.

Corinne Danan

Co-founder of HalioDx, Pharma/Biotech Entrepreneur (Eli Lilly, Qiagen, HalioDx, Veracyte), Board Director

Corinne is a senior executive with extensive experience in business development and biopharma partnerships in diagnostics. She held leadership roles at Ipsogen and later at QIAGEN, contributing to the expansion of molecular and oncology diagnostics. At HalioDx, she served as Executive Vice President, Partnerships Business Unit, building global collaborations with pharmaceutical companies in immuno-oncology and translational medicine. Following the acquisition by Veracyte, she became General Manager of the Biopharma Business Unit, leading strategic alliances and companion diagnostic programs worldwide. At Helio Diagnostics, Corinne brings her expertise in biopharma alliances and BD strategy to support the company’s growth as a leading European CDMO.

Vincent Fert

Founder of Ipsogen and HalioDx, Board Director at Helio Diagnostics, expert in innovation and international growth

Vincent is a life sciences entrepreneur with 25+ years of experience in molecular diagnostics and immuno-oncology. He co-founded Ipsogen, a pioneer in blood cancer molecular testing that was later acquired by QIAGEN, where he helped establish a global leadership position in hematology. In 2014, he founded HalioDx, dedicated to advancing precision immuno-oncology with the Immunoscore® platform, which became a reference in immune-based cancer diagnostics and was acquired by Veracyte in 2021. Throughout his career, Vincent has raised significant funding, built international partnerships, and successfully guided companies from innovation through global commercialization. At Helio Diagnostics, he contributes his strategic insight and entrepreneurial vision to support the company’s ambition of becoming a leading European CDMO for in vitro diagnostics.

Philippe Dhamelincourt

Experienced investor driving growth across diagnostics and healthcare (MatInvest)

Philippe is a seasoned investor with nearly four decades of experience in French private equity and venture capital, especially in growth ventures. He is President of Matignon Investissement & Gestion and has been involved in numerous financing and board roles across technology, healthcare, and life sciences sectors. He holds credentials as a chartered accountant and is an alumnus of ESCP Business School. At Helio Diagnostics, Philippe brings his deep financial acumen, network, and governance experience to support strategic growth and capital development.

Fabienne Hermitte

Specialist in Clinical, Medical & Regulatory Affairs, 25+ ys bringing IVD products to market (Ipsogen, Qiagen, HalioDx, Veracyte)

Fabienne has 25+ years of experience in regulatory affairs and clinical development for diagnostics. At HalioDx, she led medical, clinical and regulatory initiatives that enabled the development, validation, and global deployment of innovative immuno-oncology diagnostic solutions. She masters quality systems regulations (ISO13485, IVDR, FDA, MDSAP). With a track record in oncology, immunology, infectious diseases and neurology, from biomarker development to international submissions, she is a recognized specialist in bringing IVD products to market under rigorous standards. At Helio Diagnostics, Fabienne provides strategic guidance on regulatory and quality excellence, supporting the company’s mission to deliver reliable, compliant, and innovative CDMO services.

Careers

Join us in shaping the future of diagnostics.

Contribute to meaningful projects

At Helio Diagnostics, we believe that innovation happens when passionate people come together with a shared mission. We offer a collaborative and entrepreneurial environment where every team member can contribute to meaningful projects that impact patient care worldwide.

JOIN US